Roche Pharma expands partnership with Cipla to improve access to oncology drugs

Our Bureau Mumbai | Updated on June 18, 2020 Published on June 18, 2020

Roche Products (India) and Cipla Ltd have entered into an agreement to improve access to innovative medicines for patients in India, the companies said.

Under the agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).

Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.

V Simpson Emmanuel, General Manager, Roche Products (India), said, “This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in the Indian healthcare system to ensure better outcomes for patient.”

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on June 18, 2020
This article is closed for comments.
Please Email the Editor